%0 Generic %A Puerta, JM %A Jiménez Velasco, A %A García, MJ %A Molina, JR %A Ruiz, C %A Ferrer, C %A Durán, MS %A Simón, I %A Clavero, E %A Avellaneda, MC %A Rosell, A %A Ballesteros, I %A Ramírez, S %A Portero, MA %A Ramírez, MJ %A Fernández, M %A Jiménez, M %A Fe, R %A Mulero, N %A López, P %T Efficacy and safety evaluation of nilotinib and dasatinib (2G -TKI) on first line treatment in 73 patients with CML-CP outside of clinical trials. Andalusian CML registry (RALMC) %D 2016 %@ 0390-6078 %U http://hdl.handle.net/10668/2445 %X Even though they were approved last June 2011 to be used on first line, it is not a common procedure to begin treatment of CML-CP with 2GTKI, despite it has been demonstrated its efficacy and safety against imatinibon ENESTnd and Dasision clinical trials. %K Dasatinib %K Humanos %K Mesilato de imatinib %K Leucemia mielogenosa crónica BCR-ABL positiva %K Pirimidinas %K Sistema de registros %K Andalucía %~